CSI Market
Sign In | Register

Cartesian Therapeutics Inc (RNAC) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access RNAC Annual Cash Flow →
Reviewing cash flow data across recent quarters allows users to assess how Cartesian Therapeutics Inc adapts its cash strategy across cycles.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2026)
3 Months 		(Dec 31 2025) (Sep 30 2025) (Jun 30 2025) (Mar 31 2025)
Operating Activities
Income-39.18
Depreciation & amortization0.62
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Asset Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation2.42
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants-0.09
Finance Lease Right Of Use Asset Amortization0.24
Fair Value Adjustment Of Contingent Value Right Liability13.80
Gain Loss On Derivative Instruments Net Pretax-
Impairment Of Intangible Assets Excluding Goodwill-
Equity Method Investment Other Than Temporary Impairment-
Increase Decrease In Contract With Customer Liability-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.85
Increase (Decrease) in Accounts Payable0.31
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-0.85
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.25
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-22.14
Investing Activities
Capital Expenditures-0.03
Sale of Capital Items0.00
Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.03
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock15.67
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Vesting Of Restricted Stock-
Proceeds From Issuance Of Common Stock And Warrants-
Payment For Settlement Of Equity Awards In Business Combination-
Payments For Contingent Value Rights Distributions-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities15.67
Effect of exchange rate on cash flow-0.01
Discontinued operations0.00
Free Cash Flow-22.16
Total Cash Flow-6.50
4 historic quarters locked

Sign in to unlock the full Cartesian Therapeutics Inc cash flow history.

Sign In Create Free Account

About Cartesian Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001453687-26-000101

Figures are derived from filed reports and may be restated. Historical data is subject to revision.